Alaunos Therapeutics, Inc. (TCRT)
TCRT Stock Price Chart
Explore Alaunos Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TCRT price movements and trends.
TCRT Company Profile
Discover essential business fundamentals and corporate details for Alaunos Therapeutics, Inc. (TCRT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Aug 2005
Employees
1.00
Website
https://www.alaunos.comCEO
Holger Weis
Description
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
TCRT Financial Timeline
Browse a chronological timeline of Alaunos Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Aug 2026
Earnings released on 15 May 2026
EPS came in at -$0.59 .
Earnings released on 31 Mar 2026
EPS came in at -$0.40 surpassing the estimated -$3.69 by +89.15%, while revenue for the quarter reached $3.00k , meeting expectations.
Earnings released on 14 Nov 2025
EPS came in at -$0.55 surpassing the estimated -$4.90 by +88.78%.
Earnings released on 14 Aug 2025
EPS came in at -$0.63 surpassing the estimated -$5.33 by +88.19%.
Earnings released on 15 May 2025
EPS came in at -$0.67 surpassing the estimated -$6.44 by +89.60%, while revenue for the quarter reached $2.00k .
Earnings released on 31 Mar 2025
EPS came in at -$0.46 surpassing the estimated -$4.50 by +89.78%, while revenue for the quarter reached $4.00k .
Earnings released on 14 Nov 2024
EPS came in at -$0.70 surpassing the estimated -$4.50 by +84.44%.
Earnings released on 14 Aug 2024
EPS came in at -$0.71 surpassing the estimated -$4.50 by +84.22%, while revenue for the quarter reached $4.00k .
Stock split effective on 18 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2024
EPS came in at -$1.10 surpassing the estimated -$4.50 by +75.56%, while revenue for the quarter reached $1.00k .
Earnings released on 2 Apr 2024
EPS came in at -$0.49 falling short of the estimated -$0.45 by -8.89%, while revenue for the quarter reached $1.00k .
Stock split effective on 1 Feb 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$6.00 falling short of the estimated -$4.50 by -33.33%.
Earnings released on 14 Aug 2023
EPS came in at -$6.00 matching the estimated -$6.00, while revenue for the quarter reached $4.00k .
Earnings released on 10 May 2023
EPS came in at -$6.00 matching the estimated -$6.00.
Earnings released on 7 Mar 2023
EPS came in at -$6.00 surpassing the estimated -$13.49 by +55.52%, while revenue for the quarter reached $11.00k .
Earnings released on 14 Nov 2022
EPS came in at -$6.00 surpassing the estimated -$17.99 by +66.65%, while revenue for the quarter reached $2.91m .
Earnings released on 15 Aug 2022
EPS came in at -$7.50 surpassing the estimated -$16.49 by +54.52%.
Earnings released on 16 May 2022
EPS came in at -$7.50 surpassing the estimated -$13.49 by +44.40%.
Earnings released on 30 Mar 2022
EPS came in at -$7.50 surpassing the estimated -$13.49 by +44.40%.
Earnings released on 8 Nov 2021
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $398.00k .
Earnings released on 13 Aug 2021
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
TCRT Stock Performance
Access detailed TCRT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
